A photo of Lauren Pommert.

Lauren P. Pommert, MD, MS


  • Pediatric Oncologist, Leukemia/Lymphoma Program, Cancer and Blood Diseases Institute
  • Assistant Professor, UC Department of Pediatrics
My goal is to provide compassionate, cutting-edge cancer treatment, symptom management and psychological support to both my patients and their families, because the diagnosis of childhood cancer and its treatments effect the entire family.

About

Biography

As a pediatric oncologist, I specialize in the care of children, adolescents and young adults with hematologic malignancies and lymphoma, particularly those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML), Hodgkin lymphoma and non-Hodgkin lymphoma. My specific interest is in caring for patients with AML, relapsed or refractory AML, and in using comprehensive leukemia genetic data to aid in therapy selection.

Since I was a young child, I have always wanted to follow in my father's footsteps and become a physician. I enjoy taking care of patients with complex conditions across various locations in the hospital — from the outpatient clinic to the intensive care unit. I am fortunate to have the opportunity to form long-lasting relationships with patients and their families and to help them through their cancer journey and into survivorship.

Part of what drew me to oncology is the ability to care for the patient as a whole. My goal is to provide compassionate, cutting-edge cancer treatment, symptom management and psychological support to both my patients and their families, because the diagnosis of childhood cancer and its treatments effect the entire family. I strive to involve many specialized team members to provide comprehensive care and ensure the best possible quality of life while patients are on their treatment journey and after its completion.

I’ve received the following awards and recognitions:

  • John H. Gladney, MD Diversity Award, Saint Louis University School of Medicine, 2013
  • Rodney M. Coe Distinction in Community Service Award, Saint Louis University School of Medicine, 2013
  • Arthur E. McElfresh Award in Pediatrics, Department of Pediatrics, Saint Louis University School of Medicine, 2013
  • Award for Excellence in Critical Care, Department of Pediatrics, Saint Louis University School of Medicine, 2016
  • Chief Fellow, Division of Hematology, Oncology and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI, 2018
  • First Place, 13th Annual Medical College of Wisconsin Fellow Research Day, 2019

With my research, I am trying to improve survival outcomes for patients with relapsed and refractory acute myeloid leukemia through the clinical investigation of novel therapeutic agents and new combinations of therapeutic agents. In addition to improving survival, I am also interested in decreasing the long-term toxicities associated with our current therapies.

I enjoy spending my free time outdoors with my family as well as cooking and cycling.

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Moskop, A; Pommert, L; Baggott, C; Prabhu, S; Pacenta, HL; Phillips, CL; Rossoff, J; Stefanski, HE; Talano, JA; Margossian, SP; et al. Blood Advances. 2022; 6:4251-4255.

Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. Pommert, L; Schafer, ES; Malvar, J; Gossai, N; Florendo, E; Pulakanti, K; Heimbruch, K; Stelloh, C; Chi, YY; Sposto, R; et al. American Journal of Hematology. 2022; 97:613-622.

Posterior Reversible Encephalopathy Syndrome in the Setting of Asparaginase-associated Pancreatitis in 2 Pediatric Patients With Acute Leukemia. Scheuermann, A; Harker-Murray, P; Pommert, L. Journal of Pediatric Hematology/Oncology. 2022; 44:e709-e712.

Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival. Pommert, L; Cooper, TM; Gerbing, RB; Brodersen, L; Loken, M; Gamis, A; Aplenc, R; Alonzo, TA; Kolb, EA. Cancers. 2022; 14.

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al. Pediatric Blood and Cancer. 2021; 68.

Chemotherapy Drug Shortages in Pediatric Oncology: A Global Public Health Crisis Threatening Our Children. Pommert, L; Tasian, SK. 2021; 18.

Novel germline TRAF3IP3 mutation in a dyad with familial acute B lymphoblastic leukemia. Pommert, L; Burns, R; Furumo, Q; Pulakanti, K; Brandt, J; Burke, MJ; Rao, S. Cancer reports.. 2021; 4.

Concurrent Imatinib Dosing With High-dose Methotrexate Leads to Acute Kidney Injury and Delayed Methotrexate Clearance in Pediatric Patients With Philadelphia Chromosome-positive B-Cell Acute Lymphoblastic Leukemia. Pommert, L; Liberio, N; Ng, JS; Egelund, TA; Siver, MJ; Katzenstein, HM; Burke, MJ. Journal of Pediatric Hematology/Oncology. 2021; 43:e296-e300.

Acute Leukemia in Infants. Ibrahimova, A; Pommert, L; Breese, EH. Current Oncology Reports. 2021; 23.

Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia. Moskop, A; Pommert, L; Thakrar, P; Talano, J; Phelan, R. Pediatric Blood and Cancer. 2021; 68.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey